These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20526441)

  • 1. Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes.
    Sharma MD
    Ther Clin Risk Manag; 2010 May; 6():233-7. PubMed ID: 20526441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical overview of saxagliptin for Type 2 diabetes management.
    Rosenstock J
    Expert Rev Endocrinol Metab; 2010 Nov; 5(6):809-823. PubMed ID: 30780831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.
    Gallwitz B
    Diabetes Metab Syndr Obes; 2010 May; 3():117-24. PubMed ID: 21437082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saxagliptin for type 2 diabetes.
    Chacra AR
    Diabetes Metab Syndr Obes; 2010 Sep; 3():325-35. PubMed ID: 21437102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saxagliptin.
    Dhillon S; Weber J
    Drugs; 2009 Oct; 69(15):2103-14. PubMed ID: 19791828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.
    Kulasa K; Edelman S
    Core Evid; 2010 Oct; 5():23-37. PubMed ID: 21042540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients.
    Konya H; Yano Y; Matsutani S; Tsunoda T; Ikawa T; Kusunoki Y; Matsuo T; Miuchi M; Katsuno T; Hamaguchi T; Miyagawa J; Namba M
    Ther Clin Risk Manag; 2014; 10():547-58. PubMed ID: 25050065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin-based therapies in type 2 diabetes mellitus.
    Chia CW; Egan JM
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3703-16. PubMed ID: 18628530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alogliptin: a new addition to the class of DPP-4 inhibitors.
    Andukuri R; Drincic A; Rendell M
    Diabetes Metab Syndr Obes; 2009 Jul; 2():117-26. PubMed ID: 21437125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saxagliptin plus metformin combination therapy.
    Scheen AJ
    Expert Rev Endocrinol Metab; 2012 Mar; 7(2):151-164. PubMed ID: 30764006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.
    Zarowitz BJ; Conner C
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):55S-67S. PubMed ID: 19947817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.